OnabotulinumtoxinA in the treatment of atypical odontalgia: description of a clinical case
DOI:
https://doi.org/10.23938/ASSN.0638Keywords:
Neuropatic pain. Atypical odontalgia. OnabotulinumtoxinA. Botulinum toxin A.Abstract
Atypical odontalgia (AO) is defined as a continuous dental pain in the area of one or several teeth, sometimes preceded by dental procedures in the absence of signs of dental pathology after complete examination. It is thought to have a neuropathic origin in which the response to local and systemic treatment is insufficient.
We present the case of a 50-year-old patient with AO after dental extraction, who presented a significant reduction in pain after local treatment with OnabotulinumtoxinA (OnabotA) in the symptomatic area. The response to the administration of OnabotA in this patient is in line with what had previously been observed in small series of cases, so it could be a therapeutic alternative in this type of pain that is difficult to control.
Downloads
References
MALACARNE A, SPIERINGS ELH, LU C, MALONEY GE. Persistent dentoalveolar pain disorder: a comprehensive review. J Endod 2018; 44: 206-211. https://doi.org/10.1016/j.joen.2017.09.009
The international classification of headache disorders. headache classification committee of the International Headache Society. 3rd ed. Cephalalgia 2018; 38; 1-211
GRAFF-RADFORD SB, SOLBERG WK. Is atypical odontalgia a psychological problem? Oral Surg Oral Med Oral Pathol 1993; 75: 579-582. https://doi.org/10.1016/0030-4220(93)90228-V
BAAD-HANSEN L. Atypical odontalgia pathophysiology and clinical management. J Oral Rehabil 2008; 35: 1-11. https://doi.org/10.1111/j.1365-2842.2007.01813.x
FORSSELL H, JÄÄSKELÄINEN S, LIST T, SVENSSON P, BAAD-HANSEN L. An update on pathophysiological mechanisms related to idiopathic oro-facial pain conditions with implications for management. J Oral Rehabil 2015; 42: 300-322. https://doi.org/10.1111/joor.12256
BAAD-HANSEN L, PIGG M, IVANOVIC SE, FARIS H, LIST T, DRANGSHOLT M et al. Intraoral somatosensory abnormalities in patients with atypical odontalgia - a controlled multi-center quantitative sensory testing study. Pain 2013; 154: 1287-1294. https://doi.org/10.1016/j.pain.2013.04.005
MELIS M, LOBO SL, CENEVIZ C, ZAWAWI K, AL-BADAWI E, MALONEY G et al. Atypical odontalgia: a review of the literature. Headache 2003; 43: 1060-1074. https://doi.org/10.1046/j.1526-4610.2003.03207.x
MARBACH JJ, RAPHAEL KG. Phantom tooth pain: a new look at an old dilemma. Pain med 2000; 1: 68-77. https://doi.org/10.1046/j.1526-4637.2000.00012.x
LIST T, LEIJON G, HELKIMO M, OSTER A, SVENSSON P. Effect of local anesthesia on atypical odontalgia: a randomized controlled trial. Pain 2006; 122: 306-314. https://doi.org/10.1016/j.pain.2006.02.005
LAKHAN SE, VELASCO DN, TEPPER D. Botulinum toxin-A for painful diabetic neuropathy: a meta-analysis. Pain Med 2015; 16: 1773-1780. https://doi.org/10.1111/pme.12728
APALLA Z, SOTIRIOU E, LALLAS A, LAZARIDOU E, IOANNIDES D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain 2013; 29: 857-864. https://doi.org/10.1097/AJP.0b013e31827a72d2
DODICK DW, TURKEL CC, DEGRYSE RE, AURORA SK, SILBERSTEIN SD, LIPTON RB et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-936. https://doi.org/10.1111/j.1526-4610.2010.01678.x
SANTOS-LASAOSA S, CUADRADO ML, GAGO-VEIGA AB, GUERRERO-PERAL AL, IRIMIA P, LÁINEZ JM et al. Evidencia y experiencia del uso de onabotulinumtoxinA en neuralgia del trigémino y cefaleas primarias distintas de la migraña crónica. Neurología 2017. https://doi.org/10.1016/j.nrl.2017.09.003
GAGO-VEIGA AB, SANTOS-LASAOSA S, CUADRADO ML, GUERRERO ÁL, IRIMIA P, LÁINEZ JM et al. Evidencia y experiencia de bótox en migraña crónica: Recomendaciones para la práctica clínica diaria. Neurología 2017. https://doi.org/10.1016/j.nrl.2017.09.008
LUSIVETTO S, GAZERANI P, CIANCHETTI C, PAVONE F. Botulinum toxin type A as a therapeutic agent against headache and related disorders. Toxins (Basel) 2015; 7: 3818-3844. https://doi.org/10.3390/toxins7093818
CUADRADO ML, GARCÍA-MORENO H, ARIAS JA, PAREJA JA. Botulinum neurotoxin type-A for the treatment of atypical odontalgia. Pain Med 201; 17: 1717-1721. https://doi.org/10.1093/pm/pnw040
GARCÍA-SÁEZ R, GUTIÉRREZ-VIEDMA Á, GONZÁLEZ-GARCÍA N, GÓMEZ-MAYORDOMO V, PORTA-ETESSAM J, CUADRADO ML. OnabotulinumtoxinA injections for atypical odontalgia: an open-label study on nine patients. J Pain Res 2018; 11: 1583-1588. https://doi.org/10.2147/JPR.S169701
HERRERO BABILONI A, KAPOS FP, NIXDORF DR. Intraoral administration of botulinum toxin for trigeminal neuropathic pain. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 121: e148-e153. https://doi.org/10.1016/j.oooo.2016.03.013
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
